Mr. Tse Ping

Mr. Tse Ping is the Founder and Chairman of the Company. He is responsible for the overall operations of CP Pharmaceutical Group. He is the founding chairman of Sino Biopharmaceutical Limited and now serves as the Chief Executive Officer of the Company. He is responsible for the overall operations of the Group. With more than 27 years of extensive experience in investment and management in the pharmaceutical industry in China, he is currently a director of CT Tianqing, Beijing Tide, NJCTT, Jiangsu CT Fenghai, Jiangsu CT Qingjiang, and CP Qingdao. He is also a director of Shanghai Fortune World Development Co., Ltd., Tianjin Chiatai Feed Tech Co., Ltd., SYN Energy Technology Co., Ltd., Chia Tai Oversea Chinese Realty Development Co., Ltd., and Karolinska Development AB (publ) (listed on NASDAQ Stockholm Exchange), and was the Chairman of the board of director and an executive director of Lamtex Holdings Limited (listed on the Stock Exchange). Mr. Tse still serves as a director of Chia Tai Qingchunbao Pharmaceutical Co., Ltd. and a council member of the Association of Pharmaceutical Biotechnology of China. Soon after the adoption of the open-up and reform policy by China, Mr. Tse started to develop his investment and business in China. He has been engaged in the pharmaceutical industry since 1991, having made equity investments in a dozen or so enterprises, and is one of the earliest and the most successful overseas investors in the PRC pharmaceutical industry. Led by Mr. Tse, CP Pharmaceutical Group now has developed to a large integrated life and healthcare enterprise, and its Hong Kong listed flagship Sino Biopharmaceutical Limited becomes a constituent of the Heng Seng Index, holding a leading position among all pharmaceutical stocks in the market and owning a number of national key high-technology enterprises. Adhering to the concept of technology innovation and building upon research and development system based on originality as well as imitation, the Group strives to develop international level, high-end biological drugs and innovative drugs and to achieve breakthroughs in different areas including medical services, medical equipment, the greater health fields, and mergers and acquisitions, and becomes an innovation driven life and healthcare enterprise with its business encompassing a fully integrated industry chain which spans from research and development to manufacture and sales of pharmaceutical products and covers management of chronic diseases and healthcare. Since incorporation, Sino Biopharmaceutical Limited continues to break its own record in terms of revenue and net profit, and was ranked one of the “Asia’s Fab 50 Companies” by Forbes Asia for three consecutive years from 2016 to 2018 and ranked 42nd by U.S. magazine Pharm Exec’s “Top 50 Companies 2019”. As a recognition for his efforts in promoting the development of the pharmaceutical industry in China, Mr. Tse was awarded a number of honours, including the prize of “World Outstanding Chinese” and an honorary Doctor Degree by the University of West Alabama, United States of America in January 2008, the “2007/2008 Asian Knowledge Management Association academician” granted by the Asian Knowledge Management Association in December 2008, and the “The Top Ten Most Leading Innovative Persons of the PRC Enterprises in 2010” jointly granted by the PRC Productivity Society and the PRC Corporation Press in June 2010. Mr. Tse was a member of the Ninth, Tenth and Eleventh National Committee of the Chinese People’s Political Consultative Conference. He is currently the executive vice chairman of the China Overseas Chinese Entrepreneurs Association and the Beijing Overseas Chinese Chamber of Commerce, and the vice chairman of the China International Council for the Promotion of Multinational Corporations.



Vice Chairwoman



Theresa Tse


Miss Tse, Theresa, was appointed as Vice Chairwoman of CP Pharmaceutical Group. Ms. Tse is the chairwoman of the Board, an executive director, and the chairwoman of the executive board committee and the nomination committee, respectively, of Sino Biopharmaceutical Limited (a listed company in Hong Kong, stock code 1177). Ms. Tse is also a director of CT Tianqing and the vice chairwoman of Beijing Tide. Ms. Tse is currently a director of Karolinska Development AB (publ) (listed on NASDAQ Stockholm Exchange), and was a non-executive director of Tianjin Binhai Teda Logistics (Group) Corporation Limited (listed on GEM of the Stock Exchange). She holds a Bachelor Degree of Science in Economics from the Wharton School of University of Pennsylvania. Throughout her coursework, she focused on the study of Finance and Healthcare. Previously, she worked in the investment, finance and business development departments of several companies. As a new generation business leader, Ms. Tse was recognised as one of the “Most Outstanding Business Women in China for 2018” by Forbes China online.





 Ms. Cheng Cheung Ling

Ms. Cheng Cheung Ling is CEO of CP Pharmceutical Limited. She is the vice chairwoman of the Board, an executive director, and a member of the executive board committee of Sino Biopharmaceutical Limited. She is the chairwoman of Beijing Tide and CP Qingdao. Ms. Cheng graduated from the Guanghua School of Management of Peking University and obtained a Master Degree in Business Administration. She is a also clinician. Ms. Cheng is one of the founders of CP Pharmaceutical Group and has made significant contribution to the development of business of the group in China. Having extensive experience in and a discerning vision for management and investment in the pharmaceutical industry, she spares no effort in promoting innovation and research and development capabilities in the industry. Being at the helm of Beijing Tide, Ms. Cheng advocates for innovations in research and development, production, sales, and management, and has led Beijing Tide to step up its efforts in developing international collaboration, with an aim to promote the rapid development of cutting-edge technologies for medical products in China. Under her leadership, Beijing Tide has achieved tremendous growth, riding on internationalization and innovation. Beijing Tide has become a leading company for the development of targeted drugs in China, ranked 41st among the “Top 100 Pharmaceutical Companies in China” for 2018 (awarded by the China National Pharmaceutical Industry Information Center) and recognized as an “Outstanding Industrial Enterprise for Pharmaceutical research and development Pipelines in China” for 2019 (awarded by the National Pharmaceutical Industry Information Annual Conference). Over the years, Ms. Cheng is committed to facilitating communication and trade between Mainland China and Hong Kong, and has done remarkable work for the purposes of promoting national cohesion and attracting investments in Hong Kong and Mainland China. She is also a devoted charity supporter, actively participating in and caring for community philanthropy. The distinguished community services provided by Ms. Cheng is well recognized by various domestic and overseas organisations. She has been appointed as a Justice of the Peace by the Government of Hong Kong SAR and awarded by a number of organizations honours such as “The 11th session of the Qindao award of Qingdao City”, “A Pioneer in Pharmaceutical Industry in China for 2019”, and one of the “Top 10 Leaders in Economy in China for 2019”. Public offices held by Ms. Cheng include being the chairwoman of the Friendship Association of the Political Consultative Conference (Hong Kong Provincial Committee), a member of the Eighth, Ninth, Tenth, Eleventh and Twelfth Standing Committees of the Shaanxi Province Chinese People’s Political Consultative Conference (and the convenor of its committee members in Hong Kong), the president of Hong Kong Belt and Road General Chamber of Commerce, and the vice president of the China Female Entrepreneurs Association.

Managing Director



 Mr. Tse, Eric S Y

Mr. Tse, Eric S Y is the managing director of CP Pharmaceutical Group, the executive director, and a member of the executive board committee of Sino Biopharmaceutical Limited. Mr. Tse is chairman of CT Tianqing. He holds a Bachelor of Science degree in Economics from the Wharton School of the University of Pennsylvania and a master degree in Management and Global Leadership from Schwarzman College, Tsinghua University. Before joining the Company in June 2018, Mr. Tse, Eric S Y served as the chief executive officer of Liepin North America, a reputable human resources company. Mr. Tse, Eric S Y founded the Penn Wharton China Summit during his time at university, and established the China Summit Foundation at the end of 2016. He was awarded the “Top Ten Outstanding Chinese American Youth” in 2018 (the list of which was jointly selected by the All America Chinese Youth Federation, the American Chinese Public Diplomacy Association, and the English “Los Angeles Post”).